Address: Ekinciler cad. No: 1, Floor: 2, 34 810 Kavacık Beykoz Istanbul,Turkey
Tel: 0216 680 29 29
Web: http://www.egisturkey.com/
Egis which is one of the leading pharmaceutical companies in Central Europe in 1913, began working on behalf of human health, same as in Turkey, the evidence of ethical approach to work with.
Separating R & D activities accounted for 8% of revenue, with 1618 licensed product Egis, producing a high purity and efficiency, the active ingredient that has been awarded a multi-molecule.
Egis has a fairly large market share in Eastern European countries, America and Japan, also provide the active ingredient. Production of high quality products with the active ingredient in its own structure contains patented.
Egis is the primary priority of human health, working with the principle of ethical approach, creative and expert team has started its operations in Turkey since April 2006.
Cardiovascular system in the world, Central Nervous System , which provides service to the respiratory and digestive system medicines Egis, Hungary, Turkey, and is located in the Central Nervous System won innovation awards medicines registered high production standard, produced, pioneering and innovative medicines in this field to create differences
continue is.
Keyman’s general manager discusses his firm’s development efforts towards vaccine production, in conjunction with TUBITAK and Hacettepe University, and their geographic expansion into Africa, Latin America, and Southeast Asia. Please…
A recent arrival from China, Lilly’s Turkey MD Daniel Lucas assesses the country’s healthcare system and raises key questions about the sustainability of the system at large going forward, and…
MSD Turkey has benefited in recent years from the ability to engage in local business development initiatives, and managing director Hatice Demiray has prioritized initiatives such as reducing internal bureaucracy…
GSK’s VP and Area GM Pharmaceuticals, Turkey and Caucasus, and chairman of Turkey’s innovative pharmaceutical association, discusses the effectiveness of the government’s current strategy for reducing the trade deficit in…
Imuneks is currently operating in the OTC market, but with three supergeneric products ready to market on the RX side, the firm has the potential to soon become one of…
Recordati’s South East regional VP, based in Istanbul, discusses Recordati Turkey’s key role as a manufacturing hub for Recordati, the importance of the Turkish market (fourth largest globally for the…
Turkey is quickly becoming a regional hub for pharmaceutical industry for management, clinical trials and manufacturing, explains the general manager of Chiesi Turkey. How important is it for the government…
Biocodex’s new general manager gives an overview of the affiliates ‘new deal’ program, and how the company has adjusted its approach to better fit the contemporary Turkish environment. What attracted…
The general manager of Daiichi Sankyo Turkey discusses his affiliate’s expansion into a regional hub, current strategies for growth in the Turkish market, and the keys behind his affiliates multiple ‘great…
Turkey’s leading pharmaceutical company is in the process of developing production facilities abroad, and it has just begun construction of a USD 100 million biotech facility; CEO Süha Taşpolatoğlu believes…
The leadership of Turkey’s newest major pharmaceutical player, Pharmactive, discuss the firm’s two pronged growth strategy, detailing their own sales objectives and prospects, as well as the opportunities that they…
Polifarma is Turkey’s largest producer of basic parenteral IV solutions with a 41 percent market share the country and growing exports across the region. According to the Chairman and CEO…
See our Cookie Privacy Policy Here
